Freelancerprofil: Computanional Biology - Bioinformatik - Thomas Mohr in Wien

Computanional Biology - Bioinformatik

Thomas Mohr | Wien | Remote
Um den Freelancer zu kontaktieren, müssen Sie eingeloggt sein
FREELANCER KONTAKTIEREN

Freelancer-Vorstellung

SPRACHEN

  • Englisch (Verhandlungssicher)
  • Spanisch (Grundkenntnisse)

Studienabschluss

Lebensmittle und Biotechnologie

FÄHIGKEITEN, KENNTNISSE UND ERFAHRUNGEN

• Thomas Mohr participated in long standing cooperations with various pharmaceutical companies and institutes (e.g. Institute of Cancer Research, Medical University of Vienna, Marlyn Neutraceuticals, Phoenix, Arizona, USA, Volopharm, Wels, Austria) that resulted in a number of papers and publications.
• Cell isolation and culture techniques (implementation as well as practice)
◦ Isolation of endothelial cells, epithelial cells, fibroblasts, peripheral blood monocytes
◦ 3D culture (matrigel embedding)
◦ High density culture (hollow fiber reactor)
◦ co-culture techniques
◦ protein-free cell culture
• Establishment of marker panels for cells for FACS and Immunocytochemistry
• ELISA techniques (implementation as well as practice)
◦ Sandwich ELISA, Fixed Cell ELISA
• PCR-Techniques
• Immunocytochemical methods (fluorescence and visible)
• Confocal microscopy
• Functional assays (cell migration, formation of 3D structures, matrigel-based cell invasion assays)
• Statistical design and analysis of experiments
• Profound knowledge of relevant analysis and statistical software (SPSS, GraphPad Prism, R, Bioconductor, FlowJo)
• Profound knowledge of -omics analysis methods (microarray, RNASeq and proteomics) with a focus on network and pathway analysis methods.
• Numerous lectures about methods in putting -omics data into biological context at the Medical University of Vienna and the Ludwig Boltzmann Institut for Cancer Research, Vienna.

REFERENZEN

upon request

SONSTIGES

Publications of the last five years

1. Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates. October 2019:100662. doi:10.1016/j.drup.2019.100662
2. Jomrich G, Hudec X, Harpain F, et al. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas. Cells. 2019;8(9):1092. doi:10.3390/cells8091092
3. Schelch K, Wagner C, Hager S, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018;39(4):534-545. doi:10.1093/carcin/bgy018
4. Linder M, Glitzner E, Srivatsa S, et al. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Mol Med. 2018;10(11). doi:10.15252/emmm.201809408
5. Koch M, Umek W, Hanzal E, et al. Serum proteomic pattern in female stress urinary incontinence. Electrophoresis. January 2018. doi:10.1002/elps.201700423
6. Heilos D, Röhrl C, Pirker C, et al. Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. Oncotarget. 2018;9(39):××××/×××××××××××××. doi:10.18632/oncotarget.25432
7. Hager S, Korbula K, Bielec B, et al. The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death Dis. 2018;9(11):1052. doi:10.1038/s××××/×××××××××××××-z
8. Wagner G, Lindroos-Christensen J, Einwallner E, et al. HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2. Sci Rep. 2017;7(1):40881. doi:10.1038/srep40881
9. Schoenhacker-Alte B, Mohr T, Pirker C, et al. Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Lett. July 2017. doi:10.1016/j.canlet.2017.07.009
10. Mohr T, Haudek-Prinz V, Slany A, Grillari J, Micksche M, Gerner C. Proteome profiling in IL-1β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PLoS ONE. 2017;12(6):e0179065. doi:10.1371/journal.pone.0179065
11. Jacobi N, Seeboeck R, Hofmann E, et al. Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget. 2017;8(64):××××/×××××××××××××. doi:10.18632/oncotarget.22475
12. Gojo J, Lötsch D, Spiegl-Kreinecker S, et al. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-oncology. March 2017. doi:10.1093/neuonc/nox027
13. Ghassemi S, Vejdovszky K, Sahin E, et al. FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 2017;8(50):××××/×××××××××××××. doi:10.18632/oncotarget.21184
14. Englinger B, Mair M, Miklos W, et al. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. Br J Cancer. 2017;116(4):489-500. doi:10.1038/bjc.2016.449
15. Drev D, Bileck A, Erdem ZN, et al. Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction. Clin Proteomics. 2017;14:33. doi:10.1186/s××××/×××××××××××××
16. Themanns M, Mueller KM, Kessler SM, et al. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Scientific Reports. 2016;6:34719. doi:10.1038/srep34719
17. Kryeziu K, Pirker C, Englinger B, et al. Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget. 2016;5(0). http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=8415. Accessed April 25, 2016.
18. Koch M, Mitulovic G, Hanzal E, et al. Urinary proteomic pattern in female stress urinary incontinence: a pilot study. Int Urogynecol J. May 2016. doi:10.1007/s××××/×××××××××××××
19. Englinger B, Lötsch D, Pirker C, et al. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget. June 2016. doi:10.18632/oncotarget.10324
20. Spiegl-Kreinecker S, Lötsch D, Ghanim B, et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. February 2015:nov010. doi:10.1093/neuonc/nov010
21. Schosserer M, Minois N, Angerer TB, et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat Commun. 2015;6:6158. doi:10.1038/ncomms7158
22. Pathria P, Gotthardt D, Prchal-Murphy M, et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology. 2015;4(4):e998529. doi:10.××××/×××××××××××××X.2014.998529
23. Mathieu V, Chantôme A, Lefranc F, et al. Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cell Mol Life Sci. April 2015. doi:10.1007/s××××/×××××××××××××
24. Grabner B, Schramek D, Mueller KM, et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015;6. doi:10.1038/ncomms7285
25. Dornetshuber-Fleiss R, Heilos D, Mohr T, et al. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology. 2015;93(3):318-331. doi:10.1016/j.bcp.2014.12.013

FREELANCER KONTAKTIEREN
Bitte loggen Sie sich ein oder registrieren Sie sich, um das Freelancer zu kontaktieren.
Neu bei projektwerk?